Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zepatier in HCV Infected G1/4 Treatment Naive Patients on Stable Opiate Substitution Therapy
NCT02895958Phase 4Terminated
- Sponsor
- Mater Misericordiae University Hospital
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of grazoprevir in hepatitis C (HCV), sponsored by Mater Misericordiae University Hospital. Primary endpoint: Sustained Viral Response at 12 weeks. Started Mar 2018; status: terminated.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02895958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02895958.